This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Alert me on articles by topic

Arch Intern Med. 2003;163:116-117.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Loop diuretics are a mainstay of therapy for many patients with various disorders associated with fluid overload.¹ These agents are inexpensive, effective, and well tolerated in the vast majority of patients. The 4 loop diuretics currently on the US market are furosemide, bumetanide, torsemide, and ethacrynic acid.² Though few comparative studies have been performed, US physicians use the first 3 drugs almost exclusively, reserving ethacrynic acid (due to its ototoxic potential) for patients who have had serious hypersensitivity reactions to "sulfas" or the other loop diuretics.^{1, 3-4} Ethacrynic acid is the only loop diuretic on the US market that does not contain a sulfonamide substituent. Unfortunately, the sole US producer of ethacrynic acid (Edecrin; Merck & Co, West Point, Pa) is currently unable to provide this drug; in fact, it has stopped production of the oral form indefinitely.⁵ This can present a dilemma to the clinician who has a patient requiring . . . [Full Text of this Article]

Report of a Case


Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sulfonamide Cross-Reactivity: Fact or Fiction?
Johnson et al.
The Annals of Pharmacotherapy 2005;39:290-301.
ABSTRACT | FULL TEXT